1. Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial).
- Author
-
van de Velde, Mirjam Esther, Kaspers, Gertjan J.L., Abbink, Floor C.H., Twisk, Jos W.R., van der Sluis, Inge M., van den Bos, Cor, van den Heuvel-Eibrink, Marry M., Segers, Heidi, Chantrain, Christophe, van der Werff Ten Bosch, Jutte, Willems, Leen, and van den Berg, Marleen H.
- Subjects
ANTIFUNGAL agents ,HETEROCYCLIC compounds ,INJECTIONS ,INTRAVENOUS therapy ,MEDICAL cooperation ,PERIPHERAL neuropathy ,ONCOLOGY ,PEDIATRICS ,RESEARCH ,STATISTICAL sampling ,VINCRISTINE ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DESCRIPTIVE statistics - Abstract
Simple Summary: We studied children with cancer who receive vincristine chemotherapy as a one-hour infusion and compared them to children who received vincristine as a push injection. We investigated if there was a difference in the development of vincristine induced peripheral neuropathy, the most common side effect of vincristine. We found that in general there were no differences between the two groups (one-hour group versus push group). However, in children using both vincristine and azole antifungals, we noticed that children who received vincristine as a one-hour infusion experienced less severe vincristine induced peripheral neuropathy compared to children who received vincristine as a push injection. Therefore, in children who require both azole antifungal medication as well as vincristine it might be beneficial to administer the vincristine as a one-hour infusion instead of a push injection. However, this finding needs to be confirmed in other studies as well. Vincristine (VCR) is a frequently used chemotherapeutic agent. However, it can lead to VCR-induced peripheral neuropathy (VIPN). In this study we investigated if one-hour infusions of VCR instead of push-injections reduces VIPN in pediatric oncology patients. We conducted a multicenter randomized controlled trial in which participants received all VCR administrations through push injections or one-hour infusions. VIPN was measured at baseline and 1–5 times during treatment using Common Terminology Criteria of Adverse Events (CTCAE) and pediatric-modified Total Neuropathy Score. Moreover, data on co-medication, such as azole antifungals, were collected. Overall, results showed no effect of administration duration on total CTCAE score or ped-mTNS score. However, total CTCAE score was significantly lower in patients receiving one-hour infusions concurrently treated with azole antifungal therapy (β = -1.58; p = 0.04). In conclusion, generally VCR administration through one-hour infusions does not lead to less VIPN compared to VCR push injections in pediatric oncology patients. However, one-hour infusions lead to less severe VIPN compared to push-injections when azole therapy is administered concurrently with VCR. These results indicate that in children treated with VCR and requiring concurrent azole therapy, one-hour infusions might be beneficial over push injections, although larger trials are needed to confirm this association. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF